Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
5.4
3.9
Journals
JCM
Special Issues
Updates on the Treatment of Glomerulonephritis
share announcement

Updates on the Treatment of Glomerulonephritis

A special issue of Journal of Clinical Medicine (ISSN 2077-0383). This special issue belongs to the section "Nephrology & Urology".

Deadline for manuscript submissions: 31 October 2024 | Viewed by 681

Special Issue Editor

Dr. Lucio Manenti

E-Mail Website
Guest Editor
Chief Physician of the Nephrology and Dialysis Unit, Azienda Socio Sanitaria Ligure 5- La Spezia, Parma, Italy
Interests: clinical nephrology; clinical rheumatology; dialysis; hemodialysis; chronic renal failure; chronic kidney failure; renal; thrombotic microangiopathy; autoimmunity; kidney

Special Issue Information

Dear Colleagues,

Recently, new therapies have become available for glomerulonephritis. This is largely due to a better understanding of the pathogenetic mechanisms that determine the onset of each individual glomerulonephritis case and the mechanisms that determine the progression of renal damage in spite of the already known immunosuppressive therapies.

In particular, new drugs acting on B lymphocytes have already been incorporated into the guidelines for certain glomerulonephritis cases, and many more are to come with targets on different inflammatory pathways (such as the complement system) or different sites (such as the endothelium).

Moreover, non-immunosoppressive drugs that would slow down the progression of kidney damage particularly in certain glomerulonephritis have been added to the nephrologist “armamentarium”.

It is therefore of paramount importance to update the field of glomerulonephritis therapies in order to facilitate an increase in the personalisation of therapies in the light of the clinical and histopathological data available.

Dr. Lucio Manenti
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • clinical nephrology
  • clinical rheumatology
  • chronic renal failure
  • chronic kidney failure
  • autoimmunity
  • complement system
  • kidney
  • treatment
  • glomerulonephritis
  • lupus nephritis
  • vasculitis
  • IgA nephropathy
  • membranous nephropathy
  • membranoproliferative glomerulonephritis

Published Papers (1 paper)

Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

9 pages, 235 KiB  
Article
Lupus Nephritis Outcomes after Stopping Immunosuppression
by Fahidah Alenzi, Oier Ateka-Barrutia, Chee Ken Cheah, Munther Khamashta, Shirish R. Sangle and David P. D’Cruz
J. Clin. Med. 2024, 13(8), 2211; https://doi.org/10.3390/jcm13082211 - 11 Apr 2024
Viewed by 469
Abstract
Background/Objectives: Immunosuppression (IS) is a standard therapy for lupus nephritis (LN). Data on the outcomes of patients with LN after the discontinuation of immunosuppression remain uncertain. This study aimed to evaluate the outcomes and results of patients with lupus nephritis (LN) who ceased [...] Read more.
Background/Objectives: Immunosuppression (IS) is a standard therapy for lupus nephritis (LN). Data on the outcomes of patients with LN after the discontinuation of immunosuppression remain uncertain. This study aimed to evaluate the outcomes and results of patients with lupus nephritis (LN) who ceased immunosuppressive (IS) therapy. Methods: Records were obtained on the clinical and laboratory features of LN patients who were treated at our Lupus Unit. They included median values and ranges for various numerical variables such as patient age, disease duration, and treatment duration. Categorical variables such as gender, LN class, IS treatment type, and patient outcomes, which were categorized as either “stable” or “flare experienced”, were presented as percentages and frequencies. A flare in LN was characterized by a two-fold increase in serum creatinine levels and a rise in proteinuria following the cessation of IS medication. Results: Outcomes were assessed for 45 patients with LN who ceased IS therapy after achieving remission. The patients’ median age was 55 years (29–78). The median duration of treatment was 4 years (0.5–14). The LN histology distribution was class V = 24.4%, class IV = 17.8 %, class III = 17.8%, class III + IV = 15.6%, class III + V = 6.7%, class IV + V = 2.2%, and class II + IV and II = 2.2%. At the discontinuation of IS treatment, creatinine levels were elevated in 9/45 (20%) patients. Furthermore, 28.9% of patients relapsed after IS treatment discontinuation. Patients with anti-Smith antibodies (anti-Sm) were observed to have a higher occurrence of relapses, with six patients experiencing flare compared to four patients who remained stable (p = 0.03). Five (38.5%) of the patients with flares had high creatinine levels after IS discontinuation. Conclusions: Most of our patients maintained clinical remission and stable levels of LN parameters after IS treatment discontinuation. Those with a high serum creatinine level, ongoing proteinuria, depleted complement levels, and the presence of anti-Sm antibodies were more likely to experience flares after the discontinuation of IS therapy. Full article
(This article belongs to the Special Issue Updates on the Treatment of Glomerulonephritis)
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-1

Planned Papers

The below list represents only planned manuscripts. Some of these manuscripts have not been received by the Editorial Office yet. Papers submitted to MDPI journals are subject to peer-review.

1. New treatment regimens and novel agents for lupus nephritis
Back to TopTop